MayoComplete Melanoma Panel, Next-Generation Sequencing, Tumor
Use
The MayoComplete Melanoma Panel is useful for identifying gene mutations in patients with melanoma for targeted therapy decisions. It is helpful in determining microsatellite instability status, which is important for assessing response to immunotherapies in solid tumors. The test evaluates formalin-fixed, paraffin-embedded tumor or cytology slides for gene mutations within a specified list of genes known to be associated with melanoma.
Special Instructions
A pathology report must accompany the specimen, including patient name, block number, tissue collection date, and source of the tissue. Forms are required if not ordering electronically.
Limitations
This test does not assess germline alterations. It cannot differentiate between somatic and germline variations, and a negative result does not rule out variants below the detection threshold. Multiple types of mutations, including small delins, are detectable, but larger structural alterations and epigenetic modifications are not. Reliable results depend on proper specimen processing; decalcified tissues may result in test failure.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
LOINC Codes
- 73977-1
- 82939-0
- 69047-9
- 48767-8
- 31208-2
- 80398-1
- 85069-3
- 62364-5
- 18771-6
Result Turnaround Time
12-20 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submit a formalin-fixed, paraffin-embedded tissue block with acceptable amount of tumor tissue or 1 hematoxylin and eosin-stained slide and 10 unstained slides with tumor tissue sections.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Ambient (preferred) |